BL
Formation Bio is an AI-native pharmaceutical company that licenses, acquires, and develops drug assets and runs clinical trials faster using a proprietary AI and software platform. Its tools include the Muse AI assistant for clinical trial operations, used internally and by partners like Sanofi to accelerate phase 3 trials.
Formation Bio is an AI-native pharmaceutical company that licenses, acquires, and develops drug assets and runs clinical trials faster using a proprietary AI and software platform. Its tools include the Muse AI assistant for clinical trial operations, used internally and by partners like Sanofi to accelerate phase 3 trials.
Founded in 2016 as TrialSpark by Benjamine Liu and Linhao Zhang to streamline clinical-trial operations. The company expanded into a full drug-development platform, in-licensing and acquiring drug assets, and in December 2023 rebranded to Formation Bio to reflect its evolution into an AI-native pharma company.
In September 2025 Formation Bio appointed Louis Brenner as CMO and Daniel Neil as CTO, with Frank D'Amelio and Dashyant Dhanak as senior advisors.
CNBC named Formation Bio to its 2025 Disruptor 50 list for its AI-native approach to drug development.
In November 2024 Formation Bio launched Muse, an AI tool built with OpenAI; Sanofi adopted it for phase 3 multiple sclerosis trials.
Formation Bio raised a $372M Series D led by Andreessen Horowitz with participation from Sanofi, Sequoia, Thrive Capital and others.
Co-Founder
Co-founder and former CTO of Formation Bio (formerly TrialSpark). Previously a software engineer at Salesforce and Oscar Insurance.
$372M raised total